Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines

Authors: Qiwei Yang, Yufeng Tian, Kelly R Ostler, Alexandre Chlenski, Lisa J Guerrero, Helen R Salwen, Lucy A Godley, Susan L Cohn

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Epigenetic aberrations and a CpG island methylator phenotype have been shown to be associated with poor outcomes in children with neuroblastoma (NB). Seven cancer related genes (THBS-1, CASP8, HIN-1, TIG-1, BLU, SPARC, and HIC-1) that have been shown to have epigenetic changes in adult cancers and play important roles in the regulation of angiogenesis, tumor growth, and apoptosis were analyzed to investigate the role epigenetic alterations play in determining NB phenotype.

Methods

Two NB cell lines (tumorigenic LA1-55n and non-tumorigenic LA1-5s) that differ in their ability to form colonies in soft agar and tumors in nude mice were used. Quantitative RNA expression analyses were performed on seven genes in LA1-5s, LA1-55n and 5-Aza-dC treated LA1-55n NB cell lines. The methylation status around THBS-1, HIN-1, TIG-1 and CASP8 promoters was examined using methylation specific PCR. Chromatin immunoprecipitation assay was used to examine histone modifications along the THBS-1 promoter. Luciferase assay was used to determine THBS-1 promoter activity. Cell proliferation assay was used to examine the effect of 5-Aza-dC on NB cell growth. The soft agar assay was used to determine the tumorigenicity.

Results

Promoter methylation values for THBS-1, HIN-1, TIG-1, and CASP8 were higher in LA1-55n cells compared to LA1-5s cells. Consistent with the promoter methylation status, lower levels of gene expression were detected in the LA1-55n cells. Histone marks associated with repressive chromatin states (H3K9Me3, H3K27Me3, and H3K4Me3) were identified in the THBS-1 promoter region in the LA1-55n cells, but not the LA1-5s cells. In contrast, the three histone codes associated with an active chromatin state (acetyl H3, acetyl H4, and H3K4Me3) were present in the THBS-1 promoter region in LA1-5s cells, but not the LA1-55n cells, suggesting that an accessible chromatin structure is important for THBS-1 expression. We also show that 5-Aza-dC treatment of LA1-55n cells alters the DNA methylation status and the histone code in the THBS-1 promoter modifies cell morphology, and inhibits their ability to form colonies in soft agar.

Conclusion

Our results suggest that epigenetic aberrations contribute to NB phenotype, and that tumorigenic properties can be inhibited by reversing the epigenetic changes with 5-Aza-dC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-20. 10.1016/S0140-6736(07)60983-0.CrossRefPubMed Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet. 2007, 369: 2106-20. 10.1016/S0140-6736(07)60983-0.CrossRefPubMed
2.
go back to reference Brodeur GM, Maris JM: Neuroblastoma. Principles and Practice of Pediatric Oncology. Edited by: Pizzo PA, Poplack DG. 2001, Philadelphia: Lippincott-Raven, 895-937. 4 Brodeur GM, Maris JM: Neuroblastoma. Principles and Practice of Pediatric Oncology. Edited by: Pizzo PA, Poplack DG. 2001, Philadelphia: Lippincott-Raven, 895-937. 4
3.
go back to reference Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL: Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004, 10: 8493-500. 10.1158/1078-0432.CCR-04-1331.CrossRefPubMed Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL: Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004, 10: 8493-500. 10.1158/1078-0432.CCR-04-1331.CrossRefPubMed
4.
go back to reference Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL: Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res. 2007, 13: 3191-7. 10.1158/1078-0432.CCR-06-2846.CrossRefPubMed Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL: Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res. 2007, 13: 3191-7. 10.1158/1078-0432.CCR-06-2846.CrossRefPubMed
5.
go back to reference Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Medicine. 2000, 6: 529-35. 10.1038/75007.CrossRefPubMed Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Medicine. 2000, 6: 529-35. 10.1038/75007.CrossRefPubMed
6.
go back to reference Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL: Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res. 2007, 67: 1716-24. 10.1158/0008-5472.CAN-06-2595.CrossRefPubMed Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL: Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res. 2007, 67: 1716-24. 10.1158/0008-5472.CAN-06-2595.CrossRefPubMed
7.
go back to reference Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ, Brodeur GM: Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988, 271: 291-306.PubMed Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ, Brodeur GM: Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res. 1988, 271: 291-306.PubMed
8.
go back to reference Foley J, Cohn SL, Salwen HR, Chagnovich D, Cowan J, Mason KL, Parysek LM: Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res. 1991, 51: 6338-45.PubMed Foley J, Cohn SL, Salwen HR, Chagnovich D, Cowan J, Mason KL, Parysek LM: Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line. Cancer Res. 1991, 51: 6338-45.PubMed
9.
go back to reference Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004, 4: 988-93. 10.1038/nrc1507.CrossRefPubMed Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004, 4: 988-93. 10.1038/nrc1507.CrossRefPubMed
10.
go back to reference Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T: CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65: 828-34.PubMed Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T: CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 2005, 65: 828-34.PubMed
11.
go back to reference Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, Ushijima T: Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology. 2008, 74: 50-60. 10.1159/000139124.CrossRefPubMed Abe M, Watanabe N, McDonell N, Takato T, Ohira M, Nakagawara A, Ushijima T: Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology. 2008, 74: 50-60. 10.1159/000139124.CrossRefPubMed
12.
go back to reference Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T: Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 2007, 247: 253-8. 10.1016/j.canlet.2006.05.001.CrossRefPubMed Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T: Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett. 2007, 247: 253-8. 10.1016/j.canlet.2006.05.001.CrossRefPubMed
13.
go back to reference Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL: Methylation-associated Silencing of the Thrombospondin-1 Gene in Human Neuroblastoma. Cancer Res. 2003, 63: 6299-310.PubMed Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL: Methylation-associated Silencing of the Thrombospondin-1 Gene in Human Neuroblastoma. Cancer Res. 2003, 63: 6299-310.PubMed
14.
go back to reference Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL: The biologic effects of antisense N-myc expression in human neuroblastoma. Cell Growth & Differ. 1994, 5: 171-8. Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL: The biologic effects of antisense N-myc expression in human neuroblastoma. Cell Growth & Differ. 1994, 5: 171-8.
15.
go back to reference Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62: 7357-63.PubMed Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL: SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res. 2002, 62: 7357-63.PubMed
16.
go back to reference Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, Gazdar AF: Aberrant methylation of SPARC in human lung cancers. Br J Cancer. 2005, 92: 942-8. 10.1038/sj.bjc.6602376.CrossRefPubMedPubMedCentral Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K, Gazdar AF: Aberrant methylation of SPARC in human lung cancers. Br J Cancer. 2005, 92: 942-8. 10.1038/sj.bjc.6602376.CrossRefPubMedPubMedCentral
17.
go back to reference Hesson LB, Cooper WN, Latif F: Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007, 26: 7283-301. 10.1038/sj.onc.1210547.CrossRefPubMed Hesson LB, Cooper WN, Latif F: Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007, 26: 7283-301. 10.1038/sj.onc.1210547.CrossRefPubMed
18.
go back to reference Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, Long QX, Wang XZ, Zeng YX: Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003, 106: 60-5. 10.1002/ijc.11166.CrossRefPubMed Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, Long QX, Wang XZ, Zeng YX: Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003, 106: 60-5. 10.1002/ijc.11166.CrossRefPubMed
19.
go back to reference Wales MM, Biel MA, el DW, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB: p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995, 1: 570-7. 10.1038/nm0695-570.CrossRefPubMed Wales MM, Biel MA, el DW, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB: p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med. 1995, 1: 570-7. 10.1038/nm0695-570.CrossRefPubMed
20.
go back to reference Zhang B, Chambers KJ, Leprince D, Faller DV, Wang S: Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene. 2009, 28: 651-61. 10.1038/onc.2008.419.CrossRefPubMed Zhang B, Chambers KJ, Leprince D, Faller DV, Wang S: Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control. Oncogene. 2009, 28: 651-61. 10.1038/onc.2008.419.CrossRefPubMed
21.
go back to reference Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM: Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer. 2001, 85: 1878-82. 10.1054/bjoc.2001.2163.CrossRefPubMedPubMedCentral Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM: Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer. 2001, 85: 1878-82. 10.1054/bjoc.2001.2163.CrossRefPubMedPubMedCentral
22.
go back to reference Zhang J, Liu L, Pfeifer GP: Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene. 2004, 23: 2241-9. 10.1038/sj.onc.1207328.CrossRefPubMed Zhang J, Liu L, Pfeifer GP: Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene. 2004, 23: 2241-9. 10.1038/sj.onc.1207328.CrossRefPubMed
23.
go back to reference Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P, Ke Y: Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst. 2002, 94: 482-90.CrossRefPubMed Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, Smith P, Ke Y: Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst. 2002, 94: 482-90.CrossRefPubMed
24.
go back to reference Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K: HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA. 2001, 98: 9796-801. 10.1073/pnas.171138398.CrossRefPubMedPubMedCentral Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, Belina D, Razumovic J, Polyak K: HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA. 2001, 98: 9796-801. 10.1073/pnas.171138398.CrossRefPubMedPubMedCentral
25.
go back to reference Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K: HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 2005, 65: 9659-69. 10.1158/0008-5472.CAN-05-1663.CrossRefPubMed Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K: HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res. 2005, 65: 9659-69. 10.1158/0008-5472.CAN-05-1663.CrossRefPubMed
Metadata
Title
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines
Authors
Qiwei Yang
Yufeng Tian
Kelly R Ostler
Alexandre Chlenski
Lisa J Guerrero
Helen R Salwen
Lucy A Godley
Susan L Cohn
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-286

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine